EGFR and neoplasm: Pre-treatment tumor and ctDNA-based NGS target sequencing, IHC of programmed death receptor-1 ligand (PD-L1) expression, TMB and Epstein-Barr virus (EBV) status were used to stratify and assign patients to receive 1 out of 6 matched monoclonal antibody against PD1, EGFR, HER2, FGFR2 or VEGFR2 (81).